Friday, 16 October 2026European Markets

AKER CARBON CAPTUR Stock Is 18% Up In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of AKER CARBON CAPTUR (Oslo Børs Benchmark Index_GI: ACC.OL) jumped by a staggering 18.55% in 5 sessions from kr10.08 to kr11.95 at 14:22 EST on Wednesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 0.47% to kr1,210.96, following the last session's downward trend.

About AKER CARBON CAPTUR

Aker Carbon Capture ASA provides products, technology, and solutions within the field of carbon capture technologies, utilization, and storage in Norway and internationally. The company's carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. It offers carbon capture plants under the Just Catch and Big Catch brands. The company was incorporated in 2020 and is headquartered in Lysaker, Norway. Aker Carbon Capture ASA is a subsidiary of Aker Horizons Holding AS.

Earnings Per Share

As for profitability, AKER CARBON CAPTUR has a trailing twelve months EPS of kr-0.33.

Volatility

AKER CARBON CAPTUR's last week, last month's, and last quarter's current intraday variation average was a positive 4.61%, a negative 0.41%, and a positive 3.80%.

AKER CARBON CAPTUR's highest amplitude of average volatility was 7.67% (last week), 4.04% (last month), and 3.80% (last quarter).

More news about AKER CARBON CAPTUR (ACC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com